can tirzepatide cause pancreatic cancer Mounjaro & Cancer: Debunking the Myth Tirzepatide and Thyroid Cancer: UK

2003, 22 (6): 497-10.1002/humu.9199

In a recent clinical trial, adults with obesity (without diabetes) lost an average of 20.2% of their body weight with tirzepatide as compared to 13.7% with semaglutide over 72 weeks

This complex relationship means that GHRP-2 is not a magic bullet for fat loss

The analysis parameters were set according to Smart et al

Blend Composition CJC-1295 (No DAC) GHRH Analog 5mg Ipamorelin Ghrelin Agonist 5mg Reference data CJC-1295 + Ipamorelin Blend specifications Composition 5mg CJC-1295 (No DAC) + 5mg Ipamorelin CJC-1295 class Synthetic GHRH(1-29) analogue (modified, No DAC) Ipamorelin class Synthetic pentapeptide GH secretagogue (GHRP) Total amount per vial 10mg co-lyophilized blend Appearance White lyophilized powder Solubility Soluble in bacteriostatic water Purity 99.4% Research applications Where CJC-1295 + Ipamorelin Blend is used in research Areas of study described in the published literature

Some patients swear by it